Login to Your Account



Earnings Roundup

'Business is Good' for Biogen as Tysabri Sales Boost Q2

By Jennifer Boggs


Wednesday, July 27, 2011
Biogen Idec Inc. may have missed its earnings estimates by a penny, but that news was trumped by growing revenues from multiple sclerosis (MS) drug Tysabri (natalizumab), which jumped 28 percent over last year largely due to the availability of a JC virus assay to manage risk for progressive multifocal leukoencephalopathy (PML).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription